TY  - GEN
AU  - Kazda,Christof M
AU  - Ding,Ying
AU  - Kelly,Ronan P
AU  - Garhyan,Parag
AU  - Shi,Chunxue
AU  - Lim,Chay Ngee
AU  - Fu,Haoda
AU  - Watson,David E
AU  - Lewin,Andrew J
AU  - Landschulz,William H
AU  - Deeg,Mark A
AU  - Moller,David E
AU  - Hardy,Thomas A
TI  - Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249
SN  - 1935-5548
PY  - 2018///0108
KW  - Biphenyl Compounds
KW  - Diabetes Mellitus, Type 2
KW  - Glucagon
KW  - Humans
KW  - Receptors, Glucagon
KW  - antagonists & inhibitors
N1  - Publication Type: Letter; Research Support, Non-U.S. Gov't; Comment
UR  - https://doi.org/10.2337/dci16-0030
ER  -